Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909742 | 0.79 | LTA4H (0.40) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6909464 | 0.78 | L3MBTL1 (0.34) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6908589 | 0.78 | LTA4H (0.39) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6903481 | 0.74 | ALDH1A1 (0.42) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6908568 | 0.74 | L3MBTL1 (0.42) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6902733 | 0.73 | PKM (0.36) | TSHRALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL6909195 | 0.72 | ALDH1A1 (0.45) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6909270 | 0.70 | LTA4H (0.37) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6905964 | 0.69 | PKM (0.37) | LTA4HALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL6909252 | 0.69 | MAOB (0.40) | TSHRALDH1A1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | ATHEROGENICS, INC. (US) | 2003-09-18 | — | — | US | claimed |
| EP-1282445-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | Atherogenics, Inc. (US) | 2003-02-12 | — | — | EP | claimed |
| WO-2001079164-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | ATHEROGENICS, INC. (US) | 2001-10-25 | — | — | WO | claimed |
| US-6747061-B2 | ADMINISTERING AN ANTIPROLIFERATIVE AGENT IN COMBINATION WITH A POTENTIATING EFFECTIVE AMOUNT OF A N- SUBSTITUTED DITHIOCARBAMATE ESTER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ATHEROGENICS, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1282445-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | Atherogenics, Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001079164-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | ATHEROGENICS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | VCAM1, MKI67, SELL | LTA4H 1855/4885TSHR 3397/4885PDE3B 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.